Zacks Investment Research cut shares of Hill-Rom (NYSE:HRC) from a buy rating to a hold rating in a research note released on Monday.

According to Zacks, “Over the past three months, Hill-Rom outperformed its industry. The company's adjusted earnings increased 23% in the last reported quarter, marking it as the 13th consecutive quarter of double-digit growth. Hill-Rom saw a solid increase in revenues on robust domestic growth, driven by a sturdy performance in Patient Support Systems and Front Line Care. The company is currently focusing on product innovation. For the full year, it has achieved more than $300 million as new product revenues. In 2019, the company expects to generate more than $400 million in new product revenue, exceeding its 2020 objective one year in advance. On the flip side, international revenues declined with a dip in sales in Asia-Pacific. Also, foreign exchange and a tough competitive landscape remain headwinds.”

Several other research firms also recently weighed in on HRC. Morgan Stanley cut their price target on Hill-Rom from $100.00 to $98.00 and set an equal weight rating for the company in a research note on Wednesday, January 2nd. ValuEngine downgraded Hill-Rom from a buy rating to a hold rating in a research note on Thursday, October 4th. Barclays started coverage on Hill-Rom in a research note on Monday, October 15th. They set an equal weight rating and a $95.00 price target for the company. Raymond James increased their price target on Hill-Rom from $100.00 to $105.00 and gave the stock an outperform rating in a research note on Monday, November 5th. Finally, UBS Group initiated coverage on Hill-Rom in a research note on Tuesday, November 27th. They issued a buy rating and a $115.00 target price for the company. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Hill-Rom currently has a consensus rating of Buy and a consensus target price of $102.67.

Shares of Hill-Rom stock opened at $92.17 on Monday. Hill-Rom has a 1 year low of $78.16 and a 1 year high of $99.81. The firm has a market cap of $6.19 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.28 and a beta of 0.96. The company has a quick ratio of 1.30, a current ratio of 1.74 and a debt-to-equity ratio of 1.11.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.12. The company had revenue of $759.20 million during the quarter, compared to the consensus estimate of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 EPS. Equities analysts expect that Hill-Rom will post 5.13 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, December 31st. Stockholders of record on Friday, December 14th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, December 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.87%. Hill-Rom’s dividend payout ratio (DPR) is presently 16.84%.

In related news, SVP Andreas G. Frank sold 7,454 shares of the firm’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total transaction of $713,795.04. Following the transaction, the senior vice president now directly owns 27,224 shares of the company’s stock, valued at approximately $2,606,970.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. IMS Capital Management purchased a new position in Hill-Rom in the 3rd quarter worth approximately $71,000. Flagship Harbor Advisors LLC purchased a new position in Hill-Rom in the 2nd quarter worth approximately $173,000. Quantbot Technologies LP increased its stake in Hill-Rom by 270.2% in the 3rd quarter. Quantbot Technologies LP now owns 2,051 shares of the medical technology company’s stock worth $193,000 after purchasing an additional 1,497 shares during the period. First Light Asset Management LLC purchased a new position in Hill-Rom in the 3rd quarter worth approximately $202,000. Finally, CAPROCK Group Inc. purchased a new position in Hill-Rom in the 3rd quarter worth approximately $211,000. 82.55% of the stock is currently owned by institutional investors.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.